Announcement PDF RNS Number : 0586A BSF Enterprise PLC 21 September 2022 21 September 2022 BSF Enterprise PLC ("BSF" or the "Company") 3D Bio-Tissues Appoints Business Director to Commercialise City-mix™ growth agent for Lab-Grown Meat and Leather BSF Enterprise, an investment company focused on unlocking the next generation of biotech solutions and the development of lab-grown tissues, is pleased to announce that its 100% owned subsidiary, 3D Bio-Tissues (3DBT), has appointed Robert Brownlee, as Business Director. Mr. Brownlee is a highly experienced director with 15 years' experience of bringing brands in the Biotech, Clinical and Pharmaceutical industries from product launch to market leading status and will be focused on launching and driving the ongoing commercialisation of 3DBT's proprietary serum-free media concentrate, City-mix™, an animalfree cell growth agent for culturing skin, muscle and fat cells for lab-grown meat and leather. Based in Leicestershire, Robert will be working with the 3DBT team to develop a "go to market strategy" and establish global sales channels. Mr. Brownlee has held business development roles world-wide, previously heading up European sales at PeproTech EC, part of Thermo Fisher Scientific. In addition, at Technopath, part of Diploma plc, he led a newly merged Laboratory Sciences Division - amalgamating the Clinical, Biotech and Pharma Divisions - and achieving substantial revenue growth. Here, he also helped develop and implement sales strategies to take Technopath's Multichem range of products from launch to market leader status, with sales of €5M in the UK (NHS) and Ireland (HSE). This appointment is an important milestone ahead of the Company unveiling the UK's first 100% of lab-grown fillet this year, produced using City-mix™. This will be used as a showcase to potential customers such as manufacturers, distributors and wholesalers that are looking to commercialise lab-grown meat and leather for the mass market. 3DBT is already in discussions with a range of significant manufacturers across the US, Europe, Israel and China and Mr. Brownlee will be responsible for advancing these and new relationships to commercial partnership status. Of particular interest to these parties is the fact that, unlike current growth agents on the market, which are comprised of stem cells and animal by-products, City-mix™ is both animal and cruelty free. Production of Citymix™ will also be carbon-neutral, creating the potential to transform both the meat and leather industries towards net-zero targets. Che Connon, Chief Executive of 3D-Bio Tissues, said: "We are absolutely delighted to welcome Robert to the 3DBT team. Our proprietary City-mix™ growth agent provides the opportunity to make lab-grown meat and leather truly cruelty-free, as well more affordable and less carbon-intensive. With our first piece of showcase 100% lab-grown fillet on track for production over the coming months, and our production capacity for City-mix™ ramping up, Rob's experience of implementing successful sales strategies for some of the largest, biotech and pharmaceutical markets across the UK, Ireland, Europe and the US will be vital in commercialising our exciting technology." Robert Brownlee added: "I have been following the success of 3DBT and am very excited to join such an innovative and pioneering company. Cellular agriculture represents a very real means of protecting the environment and driving sustainability. I am looking forward to helping 3DBT bring its impactful solutions to the market and building on the team's strong track record of success." For further enquiries, please visit www.bsfenterprise.com or contact: BSF Enterprise PLC Geoff Baker - Non-Executive Director Via SEC Newgate below Che Connon - Executive Director Shard Capital (Broker) 0203 971 7000 Damon Heath SEC Newgate Communications) (Financial Bob Huxford 020 3757 6882 Elisabeth Cowell BSF@secnewgate.co.uk George Esmond ISIN of the Ordinary Shares is GB00BHNBDQ51 SEDOL Code is BHNBDQ5. Notes to Editors BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors. It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCLMMPTMTTTBIT